Company news

Pharvaris N.V. news in 2025

Pharvaris N.V.'s news releases, calls and decks from 2025, newest first.

View company

Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

December 2, 2025

Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

November 11, 2025

Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

November 9, 2025

Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

October 22, 2025

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

August 11, 2025

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

July 23, 2025

Pharvaris Announces Proposed Public Offering of Ordinary Shares

July 21, 2025

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

July 21, 2025

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

July 9, 2025

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

June 26, 2025

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

June 15, 2025

Pharvaris Announces Annual Meeting of Shareholders

June 9, 2025

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

June 1, 2025

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

May 18, 2025

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

May 11, 2025

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

April 6, 2025

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

March 31, 2025

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

March 2, 2025

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

March 2, 2025

Pharvaris Outlines 2025 Strategic Priorities

January 12, 2025

Decks in 2025